Glossary of Cardiac NAM Terms

---

This glossary defines key terminology used in cardiac New Approach Methodologies (NAMs), drug development, and human-relevant cardiac safety assessment. Understanding these concepts supports interpretation of cardiac NAM platforms and their role in translational pharmacology.

Batch-to-batch reproducibility refers to the consistency of biological systems across independent manufacturing runs.

A Cardiac NAM platform is a human-relevant in vitro system used to evaluate cardiac safety, electrophysiology, disease mechanisms, or therapeutic efficacy without reliance on traditional animal models.

A Cardiac Organoid is a three-dimensional, multicellular human cardiac tissue model generated from stem cell–derived populations. Cardiac organoids aim to reflect aspects of native cardiac architecture and cellular diversity, enabling evaluation of coordinated tissue-level responses, intercellular signaling, and disease phenotypes in vitro.

Cardiomorph refers to a multicellular human cardiac organoid platform designed to model structural, functional, and molecular aspects of native cardiac tissue in vitro. Cardiomorph systems integrate cardiomyocytes alongside supporting cardiac cell populations within a three-dimensional microenvironment, enabling evaluation of coordinated tissue-level responses to pharmacological or pathological stimuli. In the context of cardiac New Approach Methodologies (NAMs), Cardiomorph platforms are applied in translational safety pharmacology, disease modeling, and efficacy studies, supporting mechanistic interpretation of cardiac drug responses in a human-relevant setting.

CiPA is a regulatory-scientific initiative designed to improve proarrhythmia risk assessment by integrating multi-ion channel testing, in silico modeling, and human stem cell–derived cardiomyocyte assays.

An Engineered Heart Tissue (EHT) is a structured, laboratory-generated cardiac construct composed of human cardiac cells arranged within a defined scaffold or matrix. EHT systems are commonly used to measure contractility, electrophysiology, and pharmacological responses under controlled mechanical loading conditions.

Induced pluripotent stem cell (iPSC)-derived cardiomyocytes are human heart muscle cells generated from reprogrammed somatic cells. These cells are widely used in cardiac safety pharmacology, electrophysiology studies, and disease modeling due to their human origin and scalability.

A Microphysiological System (MPS) is an advanced in vitro platform that integrates human-derived cells within controlled microenvironmental conditions, often using microfluidic technology. Also known as “organ-on-chip” systems, MPS platforms aim to replicate aspects of tissue structure, perfusion, and functional behavior in a scalable format.

A New Approach Methodology (NAM) refers to a non-animal testing approach used to evaluate biological effects, safety, or efficacy in drug development and toxicology. NAMs may include in vitro systems, computational modeling, microphysiological platforms, or integrated testing strategies designed to provide mechanistically informative and human-relevant data.

Translational pharmacology refers to the integration of experimental and mechanistic data to inform clinical decision-making and predict human therapeutic outcomes. In the context of cardiac NAM platforms, translational pharmacology involves linking in vitro cardiac responses to potential clinical safety or efficacy signals.

A Tissue-level response reflects coordinated biological behavior across multiple interacting cell types within a multicellular construct.